EP Patent

EP2456426B1 — Ferric citrate dosage forms

Assigned to Keryx Biopharmaceuticals Inc · Expires 2026-03-18 · 0y expired

What this patent protects

Patent listed against Auryxia.

Drugs covered by this patent

Auryxia (FERRIC CITRATE) · Keryx Biopharms

Patent Metadata

Patent number: EP2456426B1
Jurisdiction: EP
Classification: —
Expires: 2026-03-18
Drug substance claim: No
Drug product claim: No
Assignee: Keryx Biopharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.